Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma
Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma
复制标题
DOI：
10.1016/j.ygyno.2012.06.012
复制
发表时间：
2012-10-01
影响因子：
4.7
通讯作者：
Lele, Shashikant
中科院分区：
文献类型：
--
作者：
Mhawech-Fauceglia, Paulette;Wang, Dan;Lele, Shashikant
目标。PAX8是一种在卵巢浆液性癌（OSC）中被发现过表达的转录因子。使用shRNA沉默PAX8导致卵巢癌细胞系细胞活力下降，提示其可作为靶向治疗剂。PAX8在OSC中的预后价值尚不清楚。本研究的目的是评估PAX8作为晚期osc患者预后的生物标志物。PAX8在148 OSC的组织芯片上进行免疫组化检测，其表达与以下临床病理变量相关：诊断年龄、肿瘤分期、最佳减容、无复发生存期（RFS）和总生存期（OS）。我们发现PAX8在61%的病例中表达。PAX8与肿瘤分期、最佳减积和疾病复发无相关性。此外，PAX8对疾病结局没有预测价值。尽管研究表明PAX8蛋白在高级别晚期OSC患者中并不是一个有用的预测指标，但在大量此类病例中，PAX8的过表达使得抑制PAX8成为一种非常有吸引力的靶向治疗方法。(C) 2012爱思唯尔公司版权所有。
Objectives. Pair-Box 8 (PAX8) is a transcription factor which has been found to be overexpressed in ovarian serous carcinoma (OSC). Silencing PAX8 by using shRNA led to a drop in cell viability in ovarian cancer cell lines, suggesting its use as a targeted therapeutic agent. The prognostic value of PAX8 in OSC is still widely unknown. The aim of this study was to evaluate PAX8 as a prognostic biomarker in patients with advanced stage OSC.Methods. PAX8 was evaluated using immunohistochemistry on a tissue microarray of 148 OSC and the expression was correlated to the following clinico-pathologic variables; age of diagnosis, tumor stage, optimal debulking, recurrence free survival (RFS) and overall survival (OS).Results. We found that PAX8 was expressed in 61% of cases. There was no association between PAX8 and tumor stage, optimal debulking and disease recurrence. In addition, PAX8 failed to have a predictive value in disease outcome.Conclusion. Despite showing that PAX8 protein is not a useful predictive marker in patients with high grade, advanced stage OSC, its overexpression in a large number of these cases makes the inhibition of PAX8 a very attractive targeted therapy. (C) 2012 Elsevier Inc. All rights reserved.